{
  "id": 20686048,
  "title": "Kratos Defense president Carrai sells $209,125 of common stock",
  "url": "https://urgent.news/2026/11/19/kratos-defense-president-carrai-sells-209-125-of-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T01:31:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/kratos-defense-president-carrai-sells-209125-of-common-stock-93CH-5037509"
  },
  "original_language": "en",
  "account": "Phillip D. Carrai, President of Kratos Defense & Security Solutions, Inc. (KTOS), sold 6,500 shares of the company's common stock for about $209,125 on November 16, 2026. The transactions were carried out via a pre-set 10b5-1 plan, initiated on August 26, 2025, and involved two separate blocks of shares. The first block included 4,900 shares, sold at an average price of $31.92, while the second block consisted of 1,600 shares, sold at an average price of $32.96. After these sales, Mr. Carrai retains 162,770 shares of Kratos Defense common stock. Currently, KTOS stock is near its 52-week low of $29.98, following a 13% drop over the past week and a 57% decrease over the past year. Despite the stock's apparent undervaluation, investor sentiment remains cautious, with concerns over cash usage, working capital needs, and capital spending. Kratos Defense reported strong Q3 2026 earnings, surpassing expectations with adjusted earnings of $0.24 per share and revenue of $471.8 million, reflecting a 35.7% year-over-year increase. Analysts have given the company mixed reviews, with some maintaining Buy ratings and others expressing concerns.",
  "summary": null,
  "key_points": [
    "Phillip Carrai sold 6,500 KTOS shares for $209,125 on 2026-11-16",
    "Sales executed via pre-set 10b5-1 plan since August 2025",
    "Carrai retains 162,770 KTOS shares after transactions"
  ],
  "editors_take": "Executing these sales through a pre-set trading plan suggests the president is liquidating positions according to a predetermined schedule rather than reacting to the company's recent stock price decline.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}